0001209191-20-043562.txt : 20200723
0001209191-20-043562.hdr.sgml : 20200723
20200723212120
ACCESSION NUMBER: 0001209191-20-043562
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200723
FILED AS OF DATE: 20200723
DATE AS OF CHANGE: 20200723
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Florence Anthony A. Jr.
CENTRAL INDEX KEY: 0001559827
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201044889
MAIL ADDRESS:
STREET 1: 5425 WISCONSIN AVENUE, SUITE 800
CITY: CHEVY CHASE
STATE: MD
ZIP: 20815
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2020-07-23
0
0001693011
Inozyme Pharma, Inc.
INZY
0001559827
Florence Anthony A. Jr.
5425 WISCONSIN AVENUE, SUITE 800
CHEVY CHASE
MD
20815
0
0
1
0
Series A Preferred Stock
Common Stock
2000533
I
See Note 2
Series A-2 Preferred Stock
Common Stock
187156
I
See Note 2
The Series A Preferred Stock is convertible into Common Stock on a 7.473-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's selection or upon closing of the initial public offering of the Issuer's Common Stock. The shares have no expiration date.
The Reporting Person is a manager of NEA 15 GP, LLC, which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L.P. ("NEA 15"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by NEA 15 in which the Reporting Person has no pecuniary interest.
The Series A-2 Preferred Stock is convertible into Common Stock on a 7.473-for-1 basis into the number of shares of Common Stock as shown in Column 3 without payment of further consideration, at any time at the holder's selection or upon closing of the initial public offering of the Issuer's Common Stock. The shares have no expiration date.
/s/ Sasha Keough, attorney-in-fact
2020-07-23